JPRN-C000000050已完成2 期
A phase II study of stent therapy for malignant vena cava syndrome. (JIVROSG-0402) - Stent therapy for vena cava syndrome (JIVROSG-0402)
Japan Interventional Radiology in Oncology Study Group(JIVROSG)0 个研究点目标入组 28 人开始时间: 2005年8月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
Patients: age (median) 60.5y (29-91), male 16/female 12, SVC 16/ IVC 12 Technical success: 100% Angiographic success: 96.4% Clinical success: 71.4% (95% CI: 54.7-88.1%) Time-to-improvement (median): 1 day Adverse events (>=G3): 7.14
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Potential benefit for symptom relief by chemotherapy, radiotherapy, or surgery. 2) Intraluminal tumor thrombus resulting in stenosis of vena cava. 3) Floating thrombus distal to stenosis. 4) Stenoses both in superior and inferior vena cava. 5) Central venous pressure higher than 8cm H2O. 6) Deformity of cardiac cavity, cardiac tamponade or severe functional disorder oberved by electrocardiogram and ultrasound examination. 7) Stenosis existinf both in SVC and IVC. 8) Active inflammatory disease. 9) Acute active bleeding. 10) Pregnancy.
研究者
相似试验
已完成
不适用
Evaluation of stent angioplasty as a therapeutic option in the treatment of arteriosclerotic lesions of the common femoral artery.I70.20DRKS00024584niversitäts-Herzzentrum Bad Krozingen250
已完成
2 期
Phase II study of dedicated silicone stent placement on the carina between the bronchus to the right upper lobe and bronchus intermediusAirway stenotic diseasesJPRN-UMIN000001776agoya Medical Center10
已完成
不适用
Covered Stents in Treatment of Coronary Artery PerforationCoronary Artery PerforationNCT04630314Medical University of Silesia119
已完成
3 期
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701
终止
不适用
Antares Coronary Stent System to Facilitate Side Branch InterventionsCoronary artery diseaseCardiovascular - Coronary heart diseaseACTRN12609000487213TriReme Medical, Inc.300
